

Next Day Disclosure Return

(Equity issuer - changes in issued share capital and/or share buybacks)

Name of listed issuer: Wenzhou Kangning Hospital Co., Ltd.

Stock code: 2120

Date submitted: 21 April 2020

Section I must be completed by a listed issuer where there has been a change in its issued share capital which is discloseable pursuant to rule 13.25A of the Rules (the

Share repurchased on 3 April 2020 but not yet cancelled	65,900 H shares	0.0873%			
Share repurchased on 6 April 2020 but not yet cancelled	72,100 H shares	0.0955%			

We hereby confirm to the best knowledge, information and belief that, in relation to each issue of securities as set out in Section I, it has been duly authorized by the board of directors of the listed issuer and, insofar as applicable:

(Note 9)

- (i) all money due to the listed issuer in respect of the issue of securities has been received by it;
- (ii) all pre- _____ been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical *(Note 10)*;
- (v) all documents required

6. *In the context of a repurchase of shares:
“issues of shares” should be construed as “repurchases of shares”; and
“issued shares as a % of existing number of shares before relevant share issue” should be construed as “repurchased shares as a % of existing number of shares before relevant share repurchase”.*
7. *In the context of a redemption of shares:
“issues of shares” should be construed as “redemptions of shares”;
“issued shares as a % of existing number of shares before relevant share issue” should be construed as “redeemed shares as a % of existing number of shares before relevant share redemption”; and
“issue price per share” should be construed as “redemption price per share”.*
8. *The closing balance date is the date of the last relevant event being disclosed.*
9. *Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases.*
10. *“Identical” means in this context:

the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable thereon*

II.

A. Purchase report

Trading date	Number of securities purchased	Method of purchase (Note)	Price per share or highest price paid \$	Lowest price paid \$	Total paid \$
21 April 2020	68,100	On the Exchange	HK\$18.0	HK\$17.7	HK\$1,209,800
	68,100				HK\$1,209,800
Total					

B. Additional information for issuer whose primary listing is on the Exchange

1. Number of such securities purchased on the Exchange in the year to date (since ordinary resolution) (a) 683,000
 2. % of number of shares in issue at time ordinary resolution passed acquired on the Exchange since date of resolution 0.9046%
- ((a) x 100)
75,500,000

We hereby confirm that the repurchases set out in A above which were made on the Exchange were made in accordance with the Listing Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated 13 February 2020 which has been filed with the Exchange. We also confirm that any purchases set out in A above which were made on another stock exchange were made in accordance with the domestic rules applying to purchases made on that other exchange.

Note to Section II: Please state whether on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.

Submitted by: WANG Jian

(Name)

Title: Joint Company Secretary
(Director, Secretary or other duly authorised officer)